Cost-Effectiveness Analysis of Nirsevimab for Respiratory Syncytial Virus Disease Prevention in Newborns of Hong Kong.

ABSTRACT:

Background

Nirsevimab, a long-acting monoclonal antibody, was shown to prevent respiratory syncytial virus (RSV) infections in newborns. We evaluated the cost-effectiveness of nirsevimab strategies for newborns from the societal perspective in Hong Kong.

Methods

A Markov model was developed to simulate outcomes of four nirsevimab strategies in newborns: (1) year-round, (2) seasonal, (3) catch-up, and (4) no nirsevimab. Primary outcomes included RSV lower respiratory tract infections (LRTI) related events, direct and indirect costs, quality-adjusted life year (QALY) loss, and incremental cost per QALY (ICER).

Results

In base-case analysis, all strategies with nirsevimab reduced RSV-LRTI-related events. The catch-up group had the lowest QALY loss per 100,000 infants (38

SUBMITTER: Wang Y 

PROVIDER: S-EPMC12485666 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature